Emcure Pharmaceuticals on Saturday said it will acquire the remaining 20.42% stake in its subsidiary Zuventus Healthcare Ltd from minority shareholders for Rs 724.9 crore, making it a wholly owned unit.
The company’s board has approved entering into an agreement with the minority shareholders of Zuventus Healthcare for the acquisition, Emcure said in a regulatory filing, PTI reported.
“An aggregate consideration of Rs 724.9 crore (is) payable in cash in one or more tranches on closing, based on valuation,” it said.
Following the completion of the transaction, which is expected to close in the September quarter of FY26, Zuventus will become a fully owned subsidiary of Emcure. The company currently holds a 79.58% stake.
Emcure said the domestic market remains a strategic priority and full ownership of Zuventus will allow for complete financial consolidation. “This transaction will drive long-term value creation for Emcure, through alignment across its domestic business and unlock synergies,” the filing said.
Stay informed with the latest business news, updates on bank holidays and public holidays.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
The TOI Business Desk is a vigilant and dedicated team of journal...
Read MoreThe TOI Business Desk is a vigilant and dedicated team of journalists committed to delivering the latest and most relevant business news from around the world to readers of The Times of India. The primary focus of the TOI Business Desk is to keep a watchful eye on the global business landscape, covering a wide spectrum of industries, markets, economic trends, in-depth analysis, exclusive reports and breaking stories that impact businesses and economies. With a mission to provide valuable insights and updates, the desk ensures that TOI readers are well-informed about the ever-changing and dynamic world of commerce and can navigate the complexities of the business world.
Read Less
Start a Conversation
Post comment